Sunovion To Present Clinical Efficacy, Safety And Health-Related Quality Of Life Outcomes Data From Its Respiratory Franchise At The American Thoracic Society 2017 International Conference

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) will present data on multiple products from its broad chronic obstructive pulmonary disease (COPD) portfolio, including data from Phase 3 efficacy and safety studies of SUN-101/eFlow® in patients with moderate-to-very-severe COPD, at the American Thoracic Society 2017 International Conference (ATS 2017) to be held May 19-24, 2017, in Washington, D.C.

The seven poster presentations from SUN-101/eFlow® clinical studies include data that demonstrate the safety and efficacy of SUN-101/eFlow®, a long-acting muscarinic antagonist (LAMA) bronchodilator delivered via the proprietary, investigational eFlow® closed system nebulizer, developed by PARI Pharma GmbH, as well as data from a patient survey showing patient satisfaction with the eFlow® device. Sunovion will also present data from two health economics and outcomes research (HEOR) studies investigating the factors that influence the use of nebulized long-acting beta agonists (LABAs) in COPD treatment and the effect of long-acting versus short-acting bronchodilators on COPD-related re-hospitalizations.

“These presentations demonstrate our commitment to improving the lives of patients with COPD by better understanding the treatment landscape and advancing innovative treatment options, including nebulized and handheld products, for patients at various stages of the disease,” said Thomas H. Goodin, Ph.D., Senior Director, Clinical Development at Sunovion. “We look forward to presenting data from our portfolio of COPD products that highlight our mission to address unmet needs for people living with COPD.”

In October last year, Sunovion announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for SUN-101/eFlow® as a long-term, maintenance treatment of airflow obstruction in patients with moderate-to-very-severe COPD. If approved, this will be the first nebulized LAMA approved for the treatment of COPD in the U.S.

Back to news